Cytisine, a nicotine-free prescription treatment, has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) for “smoking cessation and reduction of nicotine cravings in smokers who are willing to stop smoking” with the goal of treatment being “the permanent cessation of nicotine-containing product use”.

Cytisine’s active ingredient is a plant alkaloid, which acts as a nicotine receptor partial agonist, binding to the same receptors responsible for nicotine dependence. This stimulates the release of dopamine, similar to nicotine, while also preventing nicotine from binding to the receptor, helping to alleviate nicotine withdrawal symptoms and reducing the rewarding effects of tobacco.

A pack of 100 Cytisine 1.5mg tablets (sufficient for the 25-day recommended treatment course) has a tariff list price of £115. 

For general product queries email infouk@consilienthealth.com